Q2
ACRV — Q2 2026 Financial Report Analysis
Acrivon's Q2 2026 net loss narrowed to $18.0M from $21.0M, mostly because 2025 had ACR-368 milestone costs and higher stock-based pay; $90.0M in cash is guided to last into Q4 2027, with the key serous endometrial cancer readout due in 2H 2026.